ArticleFrontiers in neurology

Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan.

Hideyo Kasai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.